
Work Here?
Evolutionary Scale provides AI-powered tools for protein science. It offers the ESM3 family of models that help scientists understand, imagine, and design proteins. The models run on massive compute and training data, including billions of natural proteins and trillions of tokens, and are accessible via APIs and platforms. An open-source version is available under a non-commercial license, with revenue coming from subscriptions and commercial licensing. The company differentiates itself by focusing on fundamental protein properties—sequences, structures, and functions—across small, medium, and large model sizes, and by adhering to a responsible development framework for safe deployment. Its goal is to accelerate discoveries in protein engineering and synthetic biology by providing practical AI tools to researchers.
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Biotechnology
Company Size
11-50
Company Stage
Seed
Total Funding
$142M
Headquarters
New York City, New York
Founded
2023
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$142M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Health Insurance
Dental Insurance
Vision Insurance
Company Equity
Flexible Work Hours
The Chan Zuckerberg Initiative (CZI) has acquired EvolutionaryScale, a company focused on AI algorithms for life sciences, as part of a restructuring to form Biohub, a new entity combining CZI Science and Chan Zuckerberg Biohub network. This will be the main philanthropic focus for Mark Zuckerberg and Priscilla Chan. EvolutionaryScale Cofounder Alex Rives will lead science at Biohub. Financial details of the acquisition were not disclosed.
Mark Zuckerberg and his wife, Priscilla Chan, are shifting their philanthropy's focus to science and AI. Lauren edmonds new follow authors and never miss a story! * Mark Zuckerberg and Priscilla Chan's charity has launched an initiative combining AI and biology. * Biohub announced the initiative on Thursday, saying it will use AI to advance scientific research. * It's the latest pivot for the charity, which originally launched to fix education and cure disease. The philanthropy that Meta CEO Mark Zuckerberg and his wife, Priscilla Chan, a pediatrician, cofounded is shifting its focus. That's good news for some, not such good news for others. In a blog post on Thursday, the couple said they would now prioritize their philanthropic efforts on Biohub, a group of biology labs it has supported since 2016. On the same day, Biohub said it would partner with EvolutionaryScale to leverage AI to "dramatically accelerate scientific progress toward understanding and addressing human disease." "When we started, our goal was to help scientists cure or prevent all diseases this century," Zuckerberg said in a press release. "With advances in AI, we now believe this may be possible much sooner. Accelerating science is the most positive impact we think we can make. So we're going all in on AI-powered biology for our next chapter." Zuckerberg and Chan have pledged to give away half their wealth, which could amount to well over $200 billion. When the couple first launched their foundation in 2015, they said it would focus on fixing education, public policy, as well as curing disease. These days, like Meta itself, the Chan Zuckerberg Initiative has pivoted from those earlier goals to focus on AI. In 2023, it laid off dozens of employees working in its education segment, ended its education policy grants portfolio, and shifted its focus away from an education tool it had previously developed. Last year, Chan said CZI would prioritize funding science. Business insider tells the innovative stories you want to know. "While CZI remains committed to our work in education and our local communities, we recognize that science is where our biggest investments and bets have been and will be made moving forward," Chan wrote in an email to staffers in 2024. Under the latest initiative, Biohub said it's committing to four scientific challenges, including "using AI to reprogram and harness the immune system for early detection, prevention, and treatment of disease." To achieve this, Biohub said it will expand its compute capacity to 10,000 GPUs by 2028. "As we make progress on these kinds of systems, we believe it might eventually become possible to achieve decades of discoveries in months," Biohub said in a press release. "We believe this will come together to unlock frontier medicine." Read next.
EvolutionaryScale, a startup focused on AI-driven protein generation, has raised $142 million in a seed round led by Nat Friedman, Daniel Gross, and Lux Capital, with Amazon and Nvidia's NVentures participating. The company introduced ESM3, an AI model for creating proteins for drug discovery and materials science. ESM3, developed initially at Meta's FAIR, aims to revolutionize protein engineering by designing proteins from first principles, enhancing disease understanding and drug development.
EvolutionaryScale, an A.I. biotech startup founded by a group of former Meta researchers, today (June 25) came out of stealth mode and released a large language model (LLM) that the company claims...
EvolutionaryScale raises $142M and launches AI model for protein discovery.
Find jobs on Simplify and start your career today
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Biotechnology
Company Size
11-50
Company Stage
Seed
Total Funding
$142M
Headquarters
New York City, New York
Founded
2023
Find jobs on Simplify and start your career today